Literature DB >> 19913651

The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective.

Mary May Robertson1, Valsamma Eapen, Andrea Eugenio Cavanna.   

Abstract

The overall international prevalence of Tourette syndrome (TS) is 1% in the majority of cultures of the world. Both TS and tics are certainly more obvious and may be more common in younger people. Moreover, TS is seen less frequently in some cultures. However, in all cultures where it has been reported, the phenomenology is similar, highlighting the biological underpinnings of the disorder. This article reviews the international prevalence, epidemiology, and clinical phenomenology of TS, from a cross-cultural perspective.

Entities:  

Mesh:

Year:  2009        PMID: 19913651     DOI: 10.1016/j.jpsychores.2009.07.010

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  65 in total

1.  Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism.

Authors:  Thomas V Fernandez; Stephan J Sanders; Ilana R Yurkiewicz; A Gulhan Ercan-Sencicek; Young-Shin Kim; Daniel O Fishman; Melanie J Raubeson; Youeun Song; Katsuhito Yasuno; Winson S C Ho; Kaya Bilguvar; Joseph Glessner; Su Hee Chu; James F Leckman; Robert A King; Donald L Gilbert; Gary A Heiman; Jay A Tischfield; Pieter J Hoekstra; Bernie Devlin; Hakon Hakonarson; Shrikant M Mane; Murat Günel; Matthew W State
Journal:  Biol Psychiatry       Date:  2011-12-14       Impact factor: 13.382

Review 2.  The genetics of Tourette disorder.

Authors:  Matthew W State
Journal:  Curr Opin Genet Dev       Date:  2011-01-27       Impact factor: 5.578

Review 3.  Advances in understanding and treatment of Tourette syndrome.

Authors:  Kevin St P McNaught; Jonathan W Mink
Journal:  Nat Rev Neurol       Date:  2011-11-08       Impact factor: 42.937

4.  Chromosomal rearrangements in Tourette syndrome: implications for identification of candidate susceptibility genes and review of the literature.

Authors:  Birgitte Bertelsen; Nanette Mol Debes; Lena E Hjermind; Liselotte Skov; Karen Brøndum-Nielsen; Zeynep Tümer
Journal:  Neurogenetics       Date:  2013-08-29       Impact factor: 2.660

Review 5.  Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Authors:  Samuel S Pappas; Daniel K Leventhal; Roger L Albin; William T Dauer
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

6.  Psychogenic pseudo-Tourette syndrome: one of Dr Johnson's maladies?

Authors:  John Grimley Evans
Journal:  J R Soc Med       Date:  2010-12       Impact factor: 5.344

7.  Tourette syndrome and socioeconomic status.

Authors:  Mark Aldred; Andrea E Cavanna
Journal:  Neurol Sci       Date:  2015-04-21       Impact factor: 3.307

8.  Tourette syndrome in an elderly patient.

Authors:  P Voitsidis; K Diamantopoulos; I Gliatas; I Diakogiannis; E Parlapani
Journal:  Hippokratia       Date:  2019 Jan-Mar       Impact factor: 0.471

Review 9.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

10.  The occasional case against broad dissemination and implementation: retaining a role for specialty care in the delivery of psychological treatments.

Authors:  Jonathan S Comer; David H Barlow
Journal:  Am Psychol       Date:  2013-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.